A Clinicopathology and Simplified Molecular Marker-Based Risk Stratification Model for Predicting 3-Year Recurrence...

Area of Science:

• Oncology
• Biomarkers
• Clinical Prognostics

Background:

• Endometrial carcinoma (EC) recurrence risk assessment benefits from integrating clinicopathological parameters and molecular biomarkers.
• Accurate prognostic tools are crucial for tailoring patient management and improving outcomes in EC.

Purpose of the Study:

• To develop and validate a predictive model for 3-year recurrence in endometrial carcinoma.
• To combine clinical pathological parameters with simple molecular features for enhanced prognostic accuracy.

Main Methods:

• A retrospective cohort of 136 EC patients was used, with data split into training (96) and test (40) sets.
• The PM-TERR (clinicopathology and simplified molecular markers-based EC tailored 3-year recurrence risk) model was developed using Stage, Grade, Pathology Type, and P53 status.
• Kaplan-Meier analysis and time-dependent ROC analysis were employed to assess predictive performance.

Main Results:

• The PM-TERR model showed a significant association with disease-free survival (DFS) in both training and test sets (P < .001).
• PM-TERR outperformed the ESMO stratification in predicting DFS, demonstrating higher predictive accuracy and AUC values.
• The model's predictive power was significantly enhanced, with increased likelihood values in both cohorts.

Conclusions:

• The PM-TERR model, integrating stage, grade, histology, and p53 status, shows potential for predicting 3-year EC recurrence.
• This retrospective study highlights the utility of combining clinical and molecular data for EC prognosis.
• Further prospective, multi-center validation is necessary to confirm the robustness and clinical applicability of the PM-TERR model.